Can a novel combination of treatments help eradicate HIV?

February 1, 2017
HIV infecting a human cell. Credit: NIH

A Case Western Reserve University School of Medicine researcher has received a $2.5 million grant from Gilead Sciences, a California-based biopharmaceutical company, to see if two so-far separately-used AIDS treatments are even more effective when used as a pair.

Lead researcher Michael M. Lederman, MD, Scott R. Inkley Professor of Medicine, and colleagues will combine interleukin-2, a protein made by the body that stimulates human killer-cells, with a lab-engineered monoclonal antibody that targets HIV.

"Administered alone, both Il-2 and certain can reduce—but not necessarily eliminate— the presence of HIV in the body," said Dr. Lederman. "Our study will go the next step and use them together. We want to see if they produce more of a wallop in tandem than when administered individually."

Both IL-2 and monoclonal antibodies that neutralize HIV have been given safely to HIV-infected persons but not yet in combination. Study participants will be monitored for safety and tolerance by study staff members.

A key goal of the study is to determine if the new combined treatment can reduce latent HIV reservoirs, which consist of cells infected with HIV but not actively producing HIV. Reservoirs, which are difficult to measure, are present even in cases of treated HIV infection where there are no detectable levels of HIV in the blood. Although not active, the reservoirs are evidence that the infection is not cured since they can be reactivated by any of a number of reasons.

IL-2 is approved by the Food and Drug Administration for treating certain cancers. It activates killer cells and also activates HIV from latency (a positive development since the activated cells die when expressing virus). Monoclonal antibodies that neutralize HIV are cloned protein antibodies that bind to the surface of HIV and keep it from infecting the body's immune cells. They also can help killer cells attack HIV infected that have been activated from latency to express virus.

In the 64-week study, patients in one treatment group will receive IL-2 and those in a second treatment group will receive IL-2 plus a monoclonal antibody that neutralizes HIV. The hope is that the size of the HIV reservoir will decrease in both groups and that the antibody will make the IL-2 treatment more potent. The study is set to include 16 patients and begin in the second half of 2017.

A previous retrospective study suggested that IL-2 treatment could decrease the size of latent HIV reservoirs. "We think it's important to try to confirm those findings in a prospective trial and just as important, see if the addition of a monoclonal antibody enhances the activity of IL-2," said Dr. Lederman.

He and his study colleagues are in discussions with the National Institutes of Health's Vaccine Research Center to determine which monoclonal antibody to use among several the Center has developed to prevent or treat HIV infection.

Other CWRU School of Medicine researchers involved in the study are Jonathan Karn, PhD, Reinberger Professor of Molecular Biology; Benigno Rodriguez, MD, associate professor of medicine; and Rafick-Pierre Sekaly, PhD, professor of pathology.

Explore further: Macrophages target tumor cells following monoclonal antibody therapy

Related Stories

Macrophages target tumor cells following monoclonal antibody therapy

January 16, 2014
Monoclonal antibodies directed against tumor antigens have proven effective for treating some forms of cancer. Despite the increasing use of monoclonal antibody therapy, it is not clear how these antibodies drive tumor removal.

Antibody combination puts HIV on the ropes

January 25, 2017
Without antiretroviral drug treatment, the majority of people infected with HIV ultimately develop AIDS, as the virus changes and evolves beyond the body's ability to control it. But a small group of infected individuals—called ...

Early study finds antibody that 'neutralizes' Zika virus

November 7, 2016
Researchers at Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis, Missouri, have isolated a human monoclonal antibody that in a mouse model "markedly reduced" infection by the ...

Researchers identify potential antibody treatment for H7 avian flu

March 9, 2016
Researchers at Vanderbilt University Medical Center have isolated human antibodies against a type of bird flu that has killed more than 200 people in China since 2012 and which may pose a worldwide pandemic threat.

FDA approves Merck's Zinplava to reduce recurrence of Clostridium difficile infection

October 25, 2016
International pharmaceutical company Merck has announced that the U.S. Food and Drug Administration (FDA) has approved Zinplava (its brand name for bezlotoxumab) to reduce recurrence of Clostridium difficile infection (CDI) ...

Immune-enhancing treatment may destabilize HIV reservoirs

July 21, 2016
Although antiretroviral therapy (ART) can reduce the amount of HIV in the blood to an undetectable level in most chronically infected people, it cannot eliminate reservoirs of HIV that persist in latently infected immune ...

Recommended for you

Three-in-one antibody protects monkeys from HIV-like virus

September 20, 2017
A three-pronged antibody made in the laboratory protected monkeys from infection with two strains of SHIV, a monkey form of HIV, better than individual natural antibodies from which the engineered antibody is derived, researchers ...

Fighting HIV on multiple fronts might lead to vaccine

September 20, 2017
A combination antibody strategy could be the key to halting the spread of HIV, according to results from two promising animal studies.

HIV-AIDS: Following your gut

September 18, 2017
Researchers at the University of Montreal Hospital Research Centre (CRCHUM) have discovered a way to slow viral replication in the gastrointestinal tract of people infected by HIV-AIDS.

Study finds cutbacks in foreign aid for HIV treatment would cause great harm

August 30, 2017
Proposed reductions in U.S. foreign aid would have a devastating impact on HIV treatment and prevention programs in countries receiving such aid, an international team of investigators reports. In their paper published online ...

Cancer drug can reactivate HIV

August 24, 2017
People living with HIV must take a combination of three or more different drugs every day for the rest of their lives. Unfortunately, by following this strict treatment plan, they can suffer from side effects ranging from ...

New injectable antiretroviral treatment proved to be as effective as standard oral therapy

August 3, 2017
Intramuscularly administered antiretroviral therapy (ART) may be as effective for HIV treatment as current oral therapies. This is the main conclusion of a Phase II clinical trial carried out by 50 research centers around ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.